局部晚期胃癌的辅助放化疗：从证据到单机构的日常临床实践
Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution.
作者信息
González-Domingo Manuel, Ulloa Cristóbal, Olivares Jorge, Estrada Sebastián, González Pablo, Cardozo Neyla
机构信息
Department of Radiation Oncology, Instituto Oncológico, Viña del Mar, 2540364, Chile.
Surgery resident, University of Valparaíso, Chile.
出版信息
Ecancermedicalscience. 2020 Nov 5;14:1137. doi: 10.3332/ecancer.2020.1137. eCollection 2020.
BACKGROUND
Gastric cancer is one of the main important causes of cancer death in Chile.
OBJECTIVE
To report the results of adjuvant radiochemotherapy in advanced gastric cancer.
MATERIAL AND METHODS
Between 2000 and 2018, 214 subjects aged 23-85 (median, 62) years with lymph node and/or serosa involvement were treated with adjuvant chemoradiotherapy after curative resection.
RESULTS
With a median follow-up of 41 months, overall 3- and 5-year survival was 54.9% and 40.85%, respectively. On multivariate analysis, the factors associated with lower survival were aged >65 years, stage group and number of lymph nodes involved.
CONCLUSION
In patients with locoregionally advanced gastric cancer treated with curative intent with surgery and adjuvant radiochemotherapy, the overall 5-year survival reported from local clinical practice is similar to that reported in randomised series and supports its use as an effective treatment for this type of patients in our country.
背景
胃癌是智利癌症死亡的主要重要原因之一。
目的
报告晚期胃癌辅助放化疗的结果。
材料与方法
2000年至2018年期间，214名年龄在23 - 85岁（中位数为62岁）、有淋巴结和/或浆膜受累的患者在根治性切除术后接受了辅助放化疗。
结果
中位随访41个月，总体3年和5年生存率分别为54.9%和40.85%。多因素分析显示，与生存率较低相关的因素为年龄>65岁、分期组和受累淋巴结数量。
结论
对于接受手术和辅助放化疗的局部晚期胃癌患者，当地临床实践报告的总体5年生存率与随机系列研究报告的相似，支持其作为我国这类患者的有效治疗方法。
Zotero 插件